Impact of Pharmacy Clinic on Diabetes Management (PharmaMD)
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring diabetes, pharmacy clinic, education, diabetes complications, hemoglobin A1c, health-care cost, 'no show' rate, compliance, diabetes core measures
Eligibility Criteria
Inclusion Criteria:
- high risk diabetes mellitus type 2 patients (hemoglobin ≥ 9%)
- not currently enrolled in PMDC.
- established with a primary care resident internal medicine or medicine-pediatrics resident.
- have a diagnosis of diabetes mellitus type 2.
Exclusion Criteria:
- Patients will be excluded if they have been seen by the PMDC within the past 3 months.
- under 18 years of age or over 75 years of age.
- documented as having type 1 diabetes or
- latent autoimmune diabetes of adults.
Sites / Locations
- Beaumont Geriatric Assessment Center
- Beaumont Outpatient Clinic
- Beaumont Internal Medicine Center
- Norton, Klein, Hug, Sabin and Maddens Internal Medicine & Primary Care Practice
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Standard of Care (SOC)
SOC and PMDC
The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.